Orthopedics Medical News about golimumab

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Rapid correction of low vitamin D status in nursing home residents

3. 2008 Exclusive Survey—Earnings: Good news for primary care income

4. Medicare pay-for-reporting effort draws fire from frustrated doctors

5. Debunking Myths in the US Healthcare System

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Golimumab: A human anti-TNF-alpha monoclonal antibody for the treatment of autoimmune joint diseases
Formulary , 09/17/09

Phung OJ et al. – Golimumab is a human anti–tumor necrosis factor (TNF)–alpha monoclonal antibody that was recently approved for the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS). In clinical trials, subcutaneous (SC) golimumab injected every 4 weeks significantly improved clinically relevant end points in all 3 disease states. Golimumab may increase the risk for upper respiratory tract infection, lymphoma, and injection–site reaction, but the incidence of these adverse events was low in clinical trials.

<< Previous
Postoperative morbidity and mortality following total knee...

Next >>
Radiographic Correlation of Hallux MP Fusion Position and Plate...